, Volume 29, Issue 5, pp 371–386 | Cite as

Modelling the Epidemiology of Infectious Diseases for Decision Analysis

A Primer
Practical Application


The number of economic evaluations related to infectious disease topics has increased over the last 2 decades. However, many such evaluations rely on models that do not take into account unique features of infectious diseases that can affect the estimated value of interventions against them. These include their transmissibility from infected to susceptible individuals, the possibility of acquiring natural immunity following recovery from infection and the uncertainties that arise as a result of their complex natural history and epidemiology. Modellers conducting economic evaluations of infectious disease interventions need to know the main features of different types of infectious disease models, the situations in which they should be applied and the effects of model choices on the cost effectiveness of interventions.



The research was undertaken in part thanks to funding from the Canada Research Chairs programme (support for Dr Brisson). The authors have no conflicts of interest.


  1. 1.
    Neumann PJ, Fang C-H, Cohen JT. 30 years of pharmaceutical cost-utility analyses. growth, diversity and methodological improvement. Pharmacoeconomics 2009; 27 (10): 861–72Google Scholar
  2. 2.
    WHO. WHO global burden of disease: 2004 update [online]. Available from URL: [Accessed 2010 Apr 17]Google Scholar
  3. 3.
    Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11 (4 Suppl.): S5–11CrossRefGoogle Scholar
  4. 4.
    World Bank. World development report 1993: investing in health. Oxford: Oxford University Press, 1993CrossRefGoogle Scholar
  5. 5.
    GAVI Alliance [online]. Available from URL: [Accessed 2011 Jan 18]
  6. 6.
    Mitchell M, Walker D, Zuber P, et al. Evidenced-based decision making about Hib vaccination. Lancet 2005; 365 (9463): 936–7PubMedCrossRefGoogle Scholar
  7. 7.
    Grassly NC, Fraser C. Mathematical models of infectious disease transmission. Nat Rev Microbiol 2008; 6 (6): 477–87PubMedGoogle Scholar
  8. 8.
    Roberts TE, Robinson S, Barton P, et al. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling. Sex Transm Infect 2006; 82 (3): 193–200PubMedCrossRefGoogle Scholar
  9. 9.
    Anonychuk AM, Tricco AC, Bauch CT, et al. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008; 26 (1): 17–32PubMedCrossRefGoogle Scholar
  10. 10.
    Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74PubMedCrossRefGoogle Scholar
  11. 11.
    Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38PubMedCrossRefGoogle Scholar
  12. 12.
    Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics 2010; 28 (6): 449–61PubMedCrossRefGoogle Scholar
  13. 13.
    Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26 Suppl. 10: K76–86CrossRefGoogle Scholar
  14. 14.
    Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12 (5-6): 343–51PubMedCrossRefGoogle Scholar
  15. 15.
    Hutubessy RC, Bendib LM, Evans DB. Critical issues in the economic evaluation of interventions against communicable diseases. Acta Trop 2001; 78 (3): 191–206PubMedCrossRefGoogle Scholar
  16. 16.
    Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9 (8): 681–98PubMedCrossRefGoogle Scholar
  17. 17.
    Welte R, Leidl R, Greiner W, et al. Health economics of infectious diseases. In: Kramer A, Kretzschmar M, Krickeberg K, editors. Modern infectious disease epidemiology: concepts, methods, mathematical models and public health. New York: Springer-Verlag, 2010Google Scholar
  18. 18.
    Beutels P, Van Doorslaer E, Van Damme P, et al. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003; 2 (5): 649–60PubMedCrossRefGoogle Scholar
  19. 19.
    Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15 (12): 1295–310PubMedCrossRefGoogle Scholar
  20. 20.
    Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191–215PubMedCrossRefGoogle Scholar
  21. 21.
    Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373 (9657): 48–57PubMedCrossRefGoogle Scholar
  22. 22.
    Glass RJ, Glass LM, Beyeler WE, et al. Targeted social distancing design for pandemic influenza. Emerg Infect Dis 2006; 12 (11): 1671–81PubMedCrossRefGoogle Scholar
  23. 23.
    Gojovic MZ, Sander B, Fisman D. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009; 181: 673–80PubMedCrossRefGoogle Scholar
  24. 24.
    Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5 (3): e74CrossRefGoogle Scholar
  25. 25.
    Zagheni E, Billari FC, Manfredi P, et al. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008; 168 (9): 1082–90PubMedCrossRefGoogle Scholar
  26. 26.
    Cooper BS, Medley GF, Stone SP, et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci USA 2004; 101 (27): 10223–8PubMedCrossRefGoogle Scholar
  27. 27.
    Kelso JK, Milne GJ, Kelly H. Simulation suggests that rapid activation of social distancing can arrest epidemic development due to a novel strain of influenza. BMC Public Health 2009; 9: 117PubMedCrossRefGoogle Scholar
  28. 28.
    Baggaley RF, Boily MC, White RG, et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20 (6): 805–12PubMedCrossRefGoogle Scholar
  29. 29.
    Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Management 2001; 42 (2): 183–206CrossRefGoogle Scholar
  30. 30.
    Wu JT, Leung GM, Lipsitch M, et al. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009; 6 (5): e1000085Google Scholar
  31. 31.
    Keeling MJ. Models of foot-and-mouth disease. Proc Biol Sci 2005; 272 (1569): 1195–202PubMedCrossRefGoogle Scholar
  32. 32.
    Truscott J, Garske T, Chis-Ster I, et al. Control of a highly pathogenic H5N1 avian influenza outbreak in the GB poultry flock. Proc R Soc B 2007; 274 (1623): 2287–95PubMedCrossRefGoogle Scholar
  33. 33.
    Fox JP, Elveback L, Scott W, et al. Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 1971; 94 (3): 179–89PubMedGoogle Scholar
  34. 34.
    Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397–409PubMedCrossRefGoogle Scholar
  35. 35.
    Anderson RM, May RM. Vaccination against rubella andmeasles: quantitative investigations of different policies. J Hyg (Lond) 1983; 90 (2): 259–325CrossRefGoogle Scholar
  36. 36.
    Ziv E, Daley CL, Blower SM. Early therapy for latent tuberculosis infection. Am J Epidemiol 2001; 153 (4): 381–5PubMedCrossRefGoogle Scholar
  37. 37.
    Hens N, Ayele GM, Goeyvaerts N, et al. Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight European countries. BMC Infect Dis 2009; 9: 187PubMedCrossRefGoogle Scholar
  38. 38.
    Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 1997; 94 (12): 6571–6PubMedCrossRefGoogle Scholar
  39. 39.
    Melegaro A, Choi YH, George R, et al. Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect Dis 2010; 1090Google Scholar
  40. 40.
    Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8 (7): 851–61PubMedCrossRefGoogle Scholar
  41. 41.
    Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 21 (1): 76–82CrossRefGoogle Scholar
  42. 42.
    Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319: 1462–7PubMedCrossRefGoogle Scholar
  43. 43.
    Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ 2010 May; 19 (5): 518–31PubMedGoogle Scholar
  44. 44.
    Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769CrossRefGoogle Scholar
  45. 45.
    Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002–2006). Vaccine 2007; 25 (8): 1355–67PubMedCrossRefGoogle Scholar
  46. 46.
    Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27 (4): 281–97PubMedCrossRefGoogle Scholar
  47. 47.
    Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among olderadults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294 (16): 2043–51PubMedCrossRefGoogle Scholar
  48. 48.
    Centers for Disease Control Prevention. Delayed onset and diminished magnitude of rotavirus activity: United States,November 2007–May 2008. MMWR Morb Mortal Wkly Rep 2008; 57 (June 25): 697–700Google Scholar
  49. 49.
    Shim E, Galvani AP. Impact of transmission dynamics onthe cost-effectiveness of rotavirus vaccination. Vaccine 2009; 27 (30): 4025–30PubMedCrossRefGoogle Scholar
  50. 50.
    Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004; 22 (31-32): 4203–14PubMedCrossRefGoogle Scholar
  51. 51.
    De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 (2): 177–81PubMedCrossRefGoogle Scholar
  52. 52.
    Edmunds WJ, Brisson M, Melegaro A, et al. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 2002; 20 (9-10): 1316–30PubMedCrossRefGoogle Scholar
  53. 53.
    Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352 (6): 570–85PubMedCrossRefGoogle Scholar
  54. 54.
    Kaye P, Malkani R, Martin S, et al. Invasive pneumococcal disease (IPD) in England and Wales after 7-valent conjugate vaccine (PCV7): potential impact of 10 and 13-valent vaccines [abstract]. 27th Annual Meeting of the European Society of Paediatric Infectious Diseases; 2008 June 9–13; Brussels [online]. Available from URL: [Accessed 2010 Apr 17]Google Scholar
  55. 55.
    Bauch CT, Anonychuk AM, Van Effelterre T, et al. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009; 29: 557–69PubMedCrossRefGoogle Scholar
  56. 56.
    Kramer A, Akmatov M, Kretzschmar M. Principles of infectious disease epidemiology. In: Kramer A, Krickeberg K, Kretschmar M, editors. Modern infectious disease epidemiology: concepts, methods, mathematical models, and public health. New York: Springer Science and Business Media, 2010CrossRefGoogle Scholar
  57. 57.
    Baguelin M, van Hoek AJ, Jit M, et al. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 2010; 28: 2370–84PubMedCrossRefGoogle Scholar
  58. 58.
    Garnett GP, Kim JJ, French K, et al. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 Suppl. 3: S3–178–S3/186Google Scholar
  59. 59.
    Briggs A, Sculpher M, Buxton M. Uncertainty in the economicevaluation of health care technologies: the role ofsensitivity analysis. Health Econ 1994; 3 (2): 95–104PubMedCrossRefGoogle Scholar
  60. 60.
    Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434–46PubMedCrossRefGoogle Scholar
  61. 61.
    Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479–500PubMedCrossRefGoogle Scholar
  62. 62.
    Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. Epub 2009 Jan 9Google Scholar
  63. 63.
    Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14 (4): 339–47PubMedCrossRefGoogle Scholar
  64. 64.
    Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg 1985; 94: 365–436CrossRefGoogle Scholar
  65. 65.
    Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5: 381–91CrossRefGoogle Scholar
  66. 66.
    Zagheni E, Billari FC, Manfredi P. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008; 168 (9): 1082–90PubMedCrossRefGoogle Scholar
  67. 67.
    Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20 (19-20): 2500–7PubMedCrossRefGoogle Scholar
  68. 68.
    International Society for Pharmacoeconomics and Outcome Research. Pharmacoeconomic guidelines around the world [online]. Available from URL: [Accessed 2010 Apr 17]Google Scholar
  69. 69.
    Nolan TM. The Australian model of immunization advice and vaccine funding. Vaccine 2010; 28S: A76–83CrossRefGoogle Scholar
  70. 70.
    Walker DG, Hutubessy R, Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010; 28 (11): 2356–9PubMedCrossRefGoogle Scholar
  71. 71.
    Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27 (44): 6121–8PubMedCrossRefGoogle Scholar
  72. 72.
    Rozenbaum MH, van Hoek AJ, Vegter S, et al. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 2008; 7 (6): 753–82PubMedCrossRefGoogle Scholar
  73. 73.
    Beutels P, Schuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8 (11): 727–33PubMedCrossRefGoogle Scholar
  74. 74.
    Keogh-Brown MR, Smith RD, Edmunds JW, et al. The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and the Netherlands. Eur J Health Econ 2010 Dec; 11 (6): 543–54PubMedCrossRefGoogle Scholar
  75. 75.
    Lamontagne E, Haacker M, Ventelou B, et al. Macroeconomic impact of HIV: the need for better modelling. Curr Opin HIV AIDS 2010; 5 (3): 249–54PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Modelling and Economics Unit, Centre for Infections, Health Protection AgencyLondonUK
  2. 2.Department of Preventive and Social MedicineLaval UniversityQuebec CityCanada
  3. 3.URESP, Centre de recherche FRSQ du CHA universitaire de QuébecQuébecCanada

Personalised recommendations